This comprehensive guide explains how eflornithine (formerly branded as Vaniqa) works to reduce unwanted facial hair by inhibiting a key enzyme in hair follicles, with clinical studies showing significant results in 58% of patients after eight weeks of use. While Vaniqa has been discontinued, the same active ingredient remains available through Oana Health at $46 per month (paid quarterly), offering an effective solution for the 40% of women who deal with unwanted facial hair and its emotional impacts.

This blog post discusses medical treatments for hirsutism, a condition causing excessive facial hair growth in women typically due to hormonal imbalances like PCOS, with a focus on both oral medications (like spironolactone) and topical solutions (like eflornithine cream).

Spironolactone offers a promising solution for individuals struggling with PCOS-related hair symptoms, working by blocking androgens that cause both hair loss on the scalp and excessive facial hair growth. While originally developed as a diuretic, this medication has shown significant success in helping patients manage these challenging symptoms, with many experiencing improved hair density and reduced facial hair growth over time.